Novartis Looks to Solidify Presence in Multiple Sclerosis Arena with Mayzent, then Ofatumumab

Chihiro Ogawa (left), Department Head, Neuroscience & Ophthalmology, Development Unit, Global Drug Development Division, Novartis Pharma K.K., Takuya Goto, Head, Neuroscience Franchise, Specialty Medicine Business Franchise, Novartis Pharma K.K. Novartis hopes to augment its presence in the Japanese multiple sclerosis...read more